Products - Ovarian cancer | Topic

Showing 30 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
20 February 2019
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 September 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 January 2024
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 April 2022
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 February 2019
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2016
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2015
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2013
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2013
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 May 2005
Published:
22 January 2003
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
9 April 2025
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 January 2026
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Ovarian cancer Products

Showing 30 products

Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]

Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]

Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Ovarian cancer Products

Showing 30 products